The Ohio State University received a $374,063 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to conduct research into the mechanisms driving sarcoidosis, a pulmonary and systemic granulomatous disease. The key objectives are to: 1) Determine if the renin-angiotensin-aldosterone system (RAAS) and activation of mineralocorticoid receptors promote sarcoidosis granuloma formation through redox signaling pathways, and 2) Assess if RAAS/mineralocorticoid receptor activation induces pro-fibrotic responses in sarcoidosis granulomas. This 2-year project aims to advance understanding of sarcoidosis disease mechanisms and identify potential therapeutic targets, including repurposing existing RAAS-modulating drugs. The research will be conducted at The Ohio State University and is expected to be completed by May 2026.
Generated 2/25/25, 2:52 AM